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Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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VigneUe	  #1:	  The	  geneYc	  basis	  of	  a	  new	  
syndrome	  with	  severe	  developmental	  
delay	  and	  cardiac	  abnormaliYes.	  
Family	  now	  in	  October	  2011,	  with	  five	  muta*on-­‐
posi*ve	  boys	  dying	  from	  the	  disease.	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These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
Mutation 
WT 
C C C 
Pro37 
Proband  
Unaffected 
Brother 
C T T G G	  T C T C 
Ser37 
C 
T 
This is the mutation we found… one nucleotide change 
out of 6 billion nucleotides in a diploid genome… 
An	  unrelated	  second	  family	  was	  also	  idenYfied,	  
due	  to	  having	  the	  same	  mutaYon,	  but	  in	  a	  
different	  geneYc	  background.	  
II-1 III-2 
Tentative name: Ogden Syndrome, in honor of where 
the first family lives, in Ogden, Utah 
Guest	  post:	  Time	  to	  bring	  human	  genome	  sequencing	  into	  the	  clinic	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systems and infrastructure to facilitate health information exchange so that 
data can be easily aggregated and studied.213 Integrating whole genome 
sequence data into health records within the learning health system model 
can provide researchers with more data to perform genome-wide analyses, 
which in turn can advance clinical care. Several Institute of Medicine (IOM) 
working groups have supported these goals, outlining the desirability of 
establishing a universal health information technology system and learning 
environment that engages health care providers and patients. The IOM 
reports recommend that such a system include both genomic and clinical 
information, increased interoperability of medical records systems, and 
reduced barriers to data sharing.214 The President’s Council of Advisors 
on Science and Technology identified the lack of sharing electronic health 
records—with patients, with a patient’s health care providers at other 
organizations, with public health agencies, and with researchers—as a barrier 
to improved health care.215
Recommendation 4.1
Funders of whole genome sequencing research, relevant clinical entities, 
and the commercial sector should facilitate explicit exchange of information 
between genomic researchers and clinicians, while maintaining robust data 
protection safeguards, so that whole genome sequence and health data can be 
shared to advance genomic medicine.
Performing all whole genome sequencing in CLIA-approved laboratories 
would remove one of the barriers to data sharing. It would help ensure that 
whole genome sequencing generates high-quality data that clinicians and 
researchers can use to draw clinically relevant conclusions. It would also 
ensure that individuals who obtain their whole genome sequence data could 
share them more confidently in patient-driven research initiatives, producing 
more meaningful data. !at said, current sequencing technologies and those 
in development are diverse and evolving, and standardization is a substantial 
challenge. Ongoing efforts, such as those by the Standardization of Clinical 
Testing working group are critical to achieving standards for ensuring the 
reliability of whole genome sequencing results, and facilitating the exchange 
and use of these data.216
Big	  QuesYon	  though:	  
 
Simulated	  structure	  of	  S37P	  mutant	  	  
?	  
Waddington	  claimed	  that	  canals	  form	  in	  the	  epigene*c	  
landscape	  during	  evolu*on,	  and	  that	  this	  heuris*c	  is	  useful	  for	  
understanding	  the	  unique	  quali*es	  of	  biological	  robustness.	  
E.	  coli	  adapYng	  to	  low	  glucose	  condiYons,	  in	  the	  context	  of	  media	  containing	  citrate.	  
–	  Richard	  Lemski	  experiment	  	  
"Finally,	  novel	  funcYons	  onen	  emerge	  in	  rudimentary	  forms	  that	  must	  be	  refined	  to	  
exploit	  the	  ecological	  opportuniYes.	  This	  three-­‐step	  process	  —	  in	  which	  potenYaYon	  
makes	  a	  trait	  possible,	  actualizaYon	  makes	  the	  trait	  manifest,	  and	  refinement	  makes	  
it	  effecYve	  —	  is	  probably	  typical	  of	  many	  new	  funcYons.”	  -­‐	  Lemski	  

Beyond	  our	  Kuhnian	  inheritance	  
A	  recent	  lecture	  by	  Prof	  Greg	  Radick	  quesYons	  our	  scienYfic	  inheritance,	  
through	  textbook	  histories	  of	  geneYcs	  and	  Thomas	  Kuhn's	  legacy	  
hUp://www.guardian.co.uk/science/the-­‐h-­‐word/2012/aug/28/thomas-­‐
kuhn	  
Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  ediYon	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Annie	  Jamieson.	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Expression	  Issues	  
•  We	  do	  not	  really	  know	  the	  expression	  of	  	  preUy	  much	  
ALL	  mutaYons	  in	  humans,	  as	  we	  have	  not	  
systemaYcally	  sequenced	  or	  karyotyped	  any	  geneYc	  
alteraYon	  in	  Thousands	  to	  Millions	  of	  randomly	  
selected	  people,	  nor	  categorized	  into	  ethnic	  classes,	  
i.e.	  clans.	  
•  There	  is	  a	  MAJOR	  clash	  of	  world-­‐views,	  i.e.	  do	  single	  
mutaYons	  drive	  outcome	  predominately,	  or	  are	  the	  
results	  modified	  substanYally	  by	  geneYc	  background	  
and/or	  environment?	  i.e.	  is	  there	  really	  such	  a	  thing	  as	  
geneYc	  determinism	  for	  MANY	  mutaYons?	  
VigneUe	  #2:	  One	  person	  with	  very	  severe	  obsessive	  compulsive	  
disorder,	  depression	  and	  intermiUent	  psychoses	  
“This	  laboratory	  test	  was	  developed,	  and	  its	  performance	  characteris*cs	  
were	  determined	  by	  the	  Illumina	  Clinical	  Services	  Laboratory	  (CLIA-­‐cer*fied,	  
CAP-­‐accredited).	  Consistent	  with	  laboratory-­‐developed	  tests,	  it	  has	  not	  been	  
cleared	  or	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  Administra*on.	  If	  you	  have	  
any	  ques*ons	  or	  concerns	  about	  what	  you	  might	  learn	  through	  your	  genome	  
sequence	  informa*on,	  you	  should	  contact	  your	  doctor	  or	  a	  gene*c	  
counselor.	  Please	  note	  that	  Illumina	  does	  not	  accept	  orders	  for	  Individual	  
Genome	  Sequencing	  services	  from	  Florida	  and	  New	  York.”	  
VigneUe	  #2:	  One	  person	  with	  very	  severe	  obsessive	  compulsive	  
disorder,	  depression	  and	  intermiUent	  psychoses	  
Table 1.  A summary of three clinically relevant genetic aberrations found in the clinical sequencing results of M.A.  
Mutations in MTHFR, BDNF,  and ChAT were found to be of potential clinical relevance for this person, as they are all implicated in 
contributing to the susceptibility and development of many neuropsychiatric disorders that resemble those present within M.A.  A 
brief summary of the characteristics of each mutation is shown, including the gene name, genomic coordinates, amino acid change, 
zygosity, mutation type, estimated population frequency and putative clinical significance. 
 
Gene name Genomic coordinates Amino acid change Zygosity Mutation type Population Frequency Clinical significance 
MTHFR chr1: 11854476 Glu>Ala heterozygous non-synon T:77% G:23% 
Susceptibility to psychoses, 
schizophrenia, occlusive vascular 
disease, neural tube defects, 
colon cancer, acute leukemia, and 
methylenetetra-hydrofolate 
reductase deficiency  
BDNF chr11: 27679916 Val>Met heterozygous non-synon C:77% T:23% 
Susceptibility to OCD, psychosis, 
and diminished response to 
exposure therapy  
CHAT chr10: 50824117 Asp>Asn heterozygous non-synon G:85% A:15% 
Susceptibility to schizophrenia and 
other psychopathological 
disorders. 
   
One	  person	  with	  very	  sever 	  obses ive	  compulsive	  disordere,	  
depression	  and	  intermiUent	  psychoses	  

Nucleus	  accumbens	  
Approximate	  projecYons	  of	  the	  medial	  forebrain	  bundle	  to	  striatum,	  basal	  forebrain	  
and	  prefrontal	  cortex	  (blue).	  Credit:	  Geoff	  B	  Hall,	  Via	  Wikimedia	  Commons	  (modified	  
for	  current	  use)	  

Fig.	  1.	  Coronal	  secYon	  of	  the	  brain	  near	  the	  nucleus	  accumbens	  with	  the	  track	  of	  
the	  electrodes	  on	  the	  len	  and	  right	  side.	  
	  
Two	  year	  follow-­‐up	  
hUp://lyonlab.cshl.edu/publicaYons.html	  
	  
Preprints:	  Lyon	  G.J.*,	  O’Rawe	  J,	  Robison	  R,	  Kiruluta	  E.S.	  ,	  Higgins	  G,	  Reese	  
M.G.	  Whole	  genome	  sequencing,	  clinical	  interpretaYon,	  and	  deep	  brain	  
sYmulaYon	  in	  a	  severely	  mentally	  ill	  person.	  2013.	  *Corresponding	  author
.	  (View	  PDF)	  (Download	  addiYonal	  files)	  
	  
Genomics	  Advisory	  Panel	  
VigneUe	  #3:	  New	  Syndrome	  with	  
Mental	  RetardaYon,	  “AuYsm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
*Private	  Photographs	  –	  Do	  not	  further	  distribute.	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old
	  	  
Dysmorphic	  
Mental	  RetardaYon	  
“auYsm”	  
“ADHD”	  
Hearing	  difficulYes	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  geneYc	  tests	  negaYve,	  including	  
negaYve	  for	  Fragile	  X	  and	  MANY	  candidate	  
genes.	  
•  Found	  one	  missense	  mutaYon	  in	  a	  known	  
mental	  retardaYon	  gene,	  but	  the	  mutaYon	  is	  a	  
very	  conservaYve	  nonsynonymous	  Asp	  to	  Glu.	  
Is	  it	  relevant	  or	  not?	  What	  about	  the	  whole	  
rest	  of	  the	  genome?	  
2	  mutaYons	  present	  in	  mother	  and	  two	  boys,	  on	  
X-­‐chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  
not	  in	  1000Genomes	  April	  2012	  release,	  and	  not	  
in	  NHLBI	  6500	  Exomes	  
	  
•  Nonsyn	  SNV	  	  	  ZNF41	  	  	  	  c.1191C>A	  	  p.Asp397Glu	  	  
	  	  
•  Nonsyn	  SNV	  	  	  TAF1	  	  	  	  	  	  	  c.4010T>C	  	  p.Ile1337Thr	  	  
	  
TAF1	  RNA	  polymerase	  II,	  TATA	  box	  binding	  protein	  
(TBP)-­‐associated	  factor,	  250kDa	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
electronically published November 18, 2003.
Address for correspondence and reprints: Dr. Vera Kalscheuer,Max-
Planck-Institute for Molecular Genetics, Ihnestrasse 73, D-14195Berlin,
Germany. E-mail: kalscheu@molgen.mpg.de
! 2003 by The American Society of Human Genetics. All rights reserved.
0002-9297/2003/7306-0013$15.00
linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
Am. J. Hum. Gen t. 73:1341–1354, 2003
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Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. Th 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that nu erous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-ch omosomal and the uto omal b eak-
point. In silico sequence analysis provided o indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that t e ntal
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
The	  two	  brothers	  with	  the	  P111L	  
mutaYons	  reported	  in	  the	  prior	  
paper	  do	  have	  mental	  deficiency,	  
hyperkinesia,	  no	  motor	  or	  
neurologic	  sign	  except	  for	  the	  
delay,	  and	  slight	  dysmorphic	  facial	  
anomalies:	  large	  low-­‐set	  ears,	  thin	  
upper	  lip,	  slight	  downward	  
palpebral	  slants,	  but	  no	  upturned	  
nose,	  and	  a	  short	  philtrum.	  The	  
mother	  was	  normal	  in	  appearance.	  	  
•  Previously	  reported	  P111L	  change	  in	  the	  
ZNF41	  protein	  has	  now	  also	  been	  found	  in	  two	  
"male	  controls"	  (EVS	  server,	  ESP6500),	  and	  
furthermore,	  there	  are	  two	  rare,	  likely	  
heterozygous	  ZNF41	  frameshin	  mutaYons	  and	  
one	  heterozygous	  stop-­‐gained	  mutaYon	  
reported	  in	  control	  individuals	  (ESP6500)	  
(personal	  communicaYon	  from	  Dr.	  Vera	  
Kalscheuer).	  	  
•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcripYon	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  finger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcripYonal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interacYon	  module	  
which	  represses	  transcripYon	  through	  recruiYng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochromaYn	  protein	  1	  (HP1)	  family,	  and	  other	  chromaYn	  
modulaYng	  proteins,	  leading	  to	  transcripYonal	  repression	  
through	  heterochromaYn	  formaYon.	  
ZNF41	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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulationmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
Proving	  Causality	  
•  Will	  need	  to	  find	  a	  second,	  unrelated	  family	  with	  same	  exact	  mu aYon	  and	  
similar	  phenotype.	  
•  Can	  also	  p rform	  in	  vitro/in	  vivo	  studies	  an 	  struct ral	  mod ling,	  and	  make	  
knock-­‐in	  mice	  and/or	  test	  in	  zebrafish,	  etc…	  for	  biological	  funcYon.	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The duplication architecture of the human genome predisposes our species to recurrent copy number
variation and disease. Emerging data suggest that this mechanism of mutation contributes to both
common and rare diseases. Two features regarding this form of mutation have emerged. First, common
structural polymorphisms create susceptible and protective chromosomal architectures. These structural
polymorphisms occur at varying frequencies in populations, leading to different susceptibility and ethnic
predilection. Second, a subset of rearrangements shows extreme variability in expressivity. We propose
that two types of genomic disorders may be distinguished: syndromic forms where the phenotypic features
are largely invariant and those where the same molecular lesion associates with a diverse set of diagnoses
including epilepsy, schizophrenia, autism, intellectual disability and congenital malformations. Copy number
variation analyses of patient genomes reveal that disease type and severity may be explained by the occur-
rence of additional rare events and their inheritance within families. We propose that the overall burden of
copy number variants creates differing sensitized backgrounds during development leading to different
thresholds and disease outcomes. We suggest that the accumulation of multiple high-penetrant alleles
of low frequency may serve as a more general model for complex genetic diseases, posing a significant
challenge for diagnostics and disease management.
INTRODUCTION
Genomic disorders were originally described as large deletions
and duplications that are highly penetrant, mostly de novo in
origin, and typically identified in affected individuals with intel-
lectual disability/multiple congenital malformations. Some
examples include Smith–Magenis syndrome (MIM: 182290),
DiGeorge/velocardiofacial syndrome (MIM: 188400, 192430)
andWilliams–Beuren syndrome (MIM: 194050). These classi-
cal genomic disorders have been well characterized in the past
two decades with genotype–phenotype correlation studies
implicating causative genes, mouse models recapitulating the
human clinical features, and standardized management proto-
cols and support groups established.
Application of higher definition molecular techniques,
including single-nucleotide polymorphism microarrays or
array comparative genomic hybridization (CGH), has allowed
genotyping of larger disease cohorts and controls. Two major
principles have emerged from these more recent studies: (i)
common copy number polymorphism predisposes certain
chromosomes to recurrent deletions and duplications and
(ii) association of the same recurrent genomic lesion with
apparently very diverse phenotypes. The latter has begun to
illuminate common neurodevelopmental pathways and
helps to explain the comorbidity of diverse neurological
manifestations within the same families. The distinction
between variability of expressivity and reduced penetrance
depending on the diagnosis has become an important consider-
ation for these rare mutational events. We will explore the
mechanisms, models and implications underlying these two
different aspects.
GENOMIC SUSCEPTIBILITY TO RECURRENT
DELETIONS AND DUPLICATIONS
Seminal work on Charcot–Marie–Tooth disease (1,2) and
hereditary neuropathy with liability to pressure palsies
(HNPP) (3) directly implicated low-copy repeats or segmental
duplications as substrates for unequal crossover or non-allelic
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Objective: The authors used a genome-
wide association study (GWAS) of multiply
affected families to investigate the associ-
ation of schizophrenia to common single-
nucleotide polymorphisms (SNPs) and rare
copy number variants (CNVs).
Method: The family sample included
2,461 individuals from 631 pedigrees (581
in the primary European-ancestry analyses).
Association was tested for single SNPs and
genetic pathways. Polygenic scores based
on family study results were used to predict
case-control status in the Schizophrenia
Psychiatric GWAS Consortium (PGC) data
set, and consistency of direction of effect
with the family study was determined for
top SNPs in the PGC GWAS analysis. Within-
family segregation was examined for
schizophrenia- ss ciated rare CNVs.
Results: No genome-wide significant asso-
ciationswereobserved for single SNPs or for
pathways. PGC case and control subjects
had significantly different genome-wide
polygenic scores (computed by weighting
their genotypes by log-odds ratios from the
family study) (best p=10217, explaining
0.4% of the variance). Family study and
PGC analyses had consistent directions for
37 of the 58 independent best PGC SNPs
(p=0.024). The overall frequency of CNVs
in regions with reported associations
with schizophrenia (chromosomes 1q21.1,
15q13.3, 16p11.2, and 22q11.2 and the
neurexin-1 gene [NRXN1]) was similar to
previou case-control studies. NRXN1
deletions and 16p11.2 duplications (both
of which were transmitted from parents)
and 22q11.2 deletions (de novo in four
cases) did not segregate with schizophre-
nia in families.
Conclusions: Many common SNPs are
likely to contribute to schizophrenia risk,
with substantial overlap in genetic risk
factors between multiply affected families
and ses in l rge case-control st dies. Our
findings are consistentwith a role for specific
CNVs in disease pathogenesis, but the partial
segregationof someCNVswith schizophrenia
suggests that researchers should exercise
caution in using them for predictive genetic
testing until their effects in diverse popula-
tions have been fully studied.
Am J Psychiatry Levinson et al.; AiA:1–11
We report here on the first genome-wide associ-
ation study (GWAS) in families with multiple members
with schizophrenia. Significant associations of single-
nucleotide polymorphisms (SNPs) can suggest new
disease susceptibility mechanisms. For schizophrenia,
large GWAS analyses of common SNPs have found
associations in the major histocompatibility complex
(MHC, chromosome 6) (1–3) and several specific genes
AJP in Advanced ajp.psychiatryonline.org 1
Article
Genome-Wide Association Study of Multiplex
Schizophrenia Pedigrees
Douglas F. Levinson, M.D.
Jianxin Shi, Ph.D.
Kai Wang, Ph.D.
Sang Oh, M.Sc.
Brien Riley, Ph.D.
Ann E. Pulver, Ph.D.
Dieter B. Wildenauer, Ph.D.
Claudine Laurent, M.D., Ph.D.
Bryan J. Mowry, M.D.,
F.R.A.N.Z.C.P.
Pablo V. Gejman, M.D.
Michael J. Owen, Ph.D.,
F.R.C.Psych.
Kenneth S. Kendler, M.D.
Gerald Nestadt, M.D.
Sibylle G. Schwab, Ph.D.
Jacques Mallet, Ph.D.
Deborah Nertney, B.Sc.
Alan R. Sanders, M.D.
Nigel M. Williams, Ph.D.
Brandon Wormley, B.S.
Virginia K. Lasseter, B.A.
Margot Albus, M.D.
Stephanie Godard-Bauché, M.S.
Madeline Alexander, Ph.D.
Jubao Duan, Ph.D.
Michael C. O’Donovan, Ph.D.,
F.R.C.Psych.
Dermot Walsh, M.D.
Anthony O’Neill, M.D.
George N. Papadimitriou, M.D.
Dimitris Dikeos, M.D.
Wolfgang Maier, M.D.
Bernard Lerer, M.D.
Dominique Campion, M.D.,
Ph.D.
David Cohen, M.D., Ph.D.
Maurice Jay, M.D.
Ayman Fanous, M.D.
Peter Eichhammer, M.D.
Jeremy M. Silverman, Ph.D.
Nadine Norton, Ph.D.
Nancy Zhang, Ph.D.
Hakon Hakonarson, M.D., Ph.D.
Cynthia Gao, M.S.
Ami Citri, Ph.D.
Mark Hansen, Ph.D.
Stephan Ripke, M.D.
The Schizophrenia Psychiatric
GWAS Consortium
Frank Dudbridge, Ph.D.
Peter A. Holmans, Ph.D.
Objective: The authors used a genome-
wide associati n study (GWAS) of multiply
affected families to investigate the associ-
ation of schizophrenia to common single-
nucleotide polymorphisms (SNPs) and rare
copy number variants (CNVs).
Method: The family sample included
2,461 in ividuals from 631 pedigrees (581
in the primary European-ancestry analyses).
Association was tested for single SNPs and
genetic pathways. Polygenic scores based
on family study results were used to predict
case-control status in the Schizophrenia
Psychiatric GWAS Consortium (PGC) data
set, and consistency of direction of effect
with the family study was determined for
top SNPs in the PGC GWAS analysis. Within-
family segregation was examined for
schizophrenia-associated rare CNVs.
Results: No genome-wide significant asso-
ciationswereobserved for single SNPs or for
pathways. PGC case and control subjects
had significantly different genome-wide
polygenic scores (computed by weighting
their genotypes by log-odds ratios from the
family study) (best p=10217, explaining
0.4% of the variance). Family study and
PGC analyses had consistent directions for
37 of the 58 independent best PGC SNPs
(p=0.024). The overall frequency of CNVs
in regions with reported associations
with schizophrenia (chromosomes 1q21.1,
15q13.3, 16p11.2, and 22q11.2 and the
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deletions and 16p11.2 duplications (both
of which were transmitted from parents)
and 22q11.2 deletions (de novo in four
cases) did not segregate with schizophre-
nia in families.
Conclusions: Many common SNPs are
likely to contribute to schizophrenia risk,
with substantial overlap in genetic risk
factors between multiply affected families
and cases in large case-control studies. Our
findings are consistentwith a role for specific
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“Rare	  CNVs	  wer 	   bserve 	  in	  regions	  with	   trong	  previ u ly	   cum n ed	  associaYon	  
with	  schizophrenia,	  but	  with	  variable	  paUerns	  of	  segregaYon.	  This	  should	  serve	  as	  a	  
reminder	  that	  we	  sYll	  know	  relaYvely	  liUle	  about	  the	  distribuYon	  of	  these	  CNVs	  in	  the	  
enYre	  populaYon	  (e.g.,	  in	  individuals	  with	  no	  or	  only	  mild	  cog iYve	  problems)	  or	  about	  
the	  reas ns	   or	  the	  emerg nce	   f	  sc izophrenia	  in	  only	  a	   inority	   f	  c rriers,	  so	  great	  
cauYon	  is	  required	  in	  geneYc	  counseling	  and	  prediagnosis.”	  	  
	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more significant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the field of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a significant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efficacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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Low concordance of multiple variant-calling
pipelines: practical implications for exome and
genome sequencing
Jason O’Rawe1,2, Tao Jiang3, Guangqing Sun3, Yiyang Wu1,2, Wei Wang4, Jingchu Hu3, Paul Bodily5, Lifeng Tian6,
Hakon Hakonarson6, W Evan Johnson7, Zhi Wei4, Kai Wang8,9* and Gholson J Lyon1,2,9*
Abstract
Background: To facilitate the clinical implementation of genomic medicine by next-generation sequencing, it will
be critically important to obtain accurate and consistent variant calls on personal genomes. Multiple software tools
for variant calling are available, but it is unclear how comparable these tools are or what their relative merits in
real-world scenarios might be.
Methods: We sequenced 15 exomes from four families using commercial kits (Illumina HiSeq 2000 platform and
Agilent SureSelect version 2 capture kit), with approximately 120X mean coverage. We analyzed the raw data using
near-default parameters with five different alignment and variant-calling pipelines (SOAP, BWA-GATK, BWA-SNVer,
GNUMAP, and BWA-SAMtools). We additionally sequenced a single whole genome using the sequencing and
analysis pipeline from Complete Genomics (CG), with 95% of the exome region being covered by 20 or more
reads per base. Finally, we validated 919 single-nucleotide variations (SNVs) and 841 insertions and deletions
(indels), including similar fractions of GATK-only, SOAP-only, and shared calls, on the MiSeq platform by amplicon
sequencing with approximately 5000X mean coverage.
Results: SNV concordance between five Illumina pipelines across all 15 exomes was 57.4%, while 0.5 to 5.1% of
variants were called as unique to each pipeline. Indel concordance was only 26.8% between three indel-calling
pipelines, even after left-normalizing and intervalizing genomic coordinates by 20 base pairs. There were 11% of
CG variants falling within targeted regions in exome sequencing that were not called by any of the Illumina-based
exome analysis pipelines. Based on targeted amplicon sequencing on the MiSeq platform, 97.1%, 60.2%, and 99.1%
of the GATK-only, SOAP-only and shared SNVs could be validated, but only 54.0%, 44.6%, and 78.1% of the GATK-
only, SOAP-only and shared indels could be validated. Additionally, our analysis of two families (one with four
individuals and the other with seven), demonstrated additional accuracy gained in variant discovery by having
access to genetic data from a multi-generational family.
Conclusions: Our results suggest that more caution should be exercised in genomic medicine settings when
analyzing individual genomes, including interpreting positive and negative findings with scrutiny, especially for
indels. We advocate for renewed collection and sequencing of multi-generational families to increase the overall
accuracy of whole genomes.
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Major	  Conclusion:	  Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	  
Pa*entsLikeMe	  
Sequenced	  whole	  genomes	  of	  Mother,	  Father	  
and	  Two	  Boys,	  using	  Complete	  Genomics	  
•  Sequenced	  “whole”	  genomes	  to	  obtain	  noncoding	  and	  
other	  non-­‐exonic	  regions.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  normal.	  
•  ~6	  million	  variants	  total	  in	  the	  4	  people	  different	  from	  
Hg19	  reference	  genome.	  
•  No	  homozygous	  autosomal	  recessive	  mutaYons	  found.	  
•  No	  Nonsense/Frameshin	  mutaYons	  in	  both	  boys.	  
•  2	  mutaYons	  present	  in	  mother	  and	  two	  boys,	  on	  X-­‐
chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  not	  in	  
1000Genomes	  April	  2012	  release,	  and	  not	  in	  NHLBI	  
6500	  Exomes	  
	  
DBS-­‐probes	  shown	  in	  X-­‐ray	  of	  the	  skull	  (white	  areas	  around	  maxilla	  and	  mandible	  
represent	  metal	  dentures	  and	  are	  unrelated	  to	  DBS	  devices)	  
“Biological	  Indeterminacy”	  
•  Bateson	  became	  famous	  as	  the	  outspoken	  
Mendelian	  antagonist	  of	  Walter	  Raphael	  Weldon,	  
his	  former	  teacher,	  and	  Karl	  Pearson	  who	  led	  the	  
biometric	  school	  of	  thinking.	  This	  concerned	  the	  
debate	  over	  saltaYonism	  versus	  gradualism	  
(Darwin	  had	  been	  a	  gradualist,	  but	  Bateson	  was	  a	  
saltaYonist).	  Later,	  Ronald	  Fisher	  and	  
J.B.S.	  Haldane	  showed	  that	  discrete	  mutaYons	  
were	  compaYble	  with	  gradual	  evoluYon:	  see	  the	  
modern	  evoluYonary	  synthesis.	  
Biological	  Indeterminacy.	  Greenspan	  RJ.	  Sci	  Eng	  
Ethics.	  2012	  Jul	  3	  
	  
•  Seguin	  E.	  1866,	  -­‐	  	  “our	  incomplete	  studies	  do	  
not	  permit	  actual	  classificaYon;	  but	  it	  is	  beUer	  
to	  leave	  things	  by	  themselves	  rather	  than	  to	  
force	  them	  into	  classes	  which	  have	  their	  
foundaYon	  only	  on	  paper”-­‐	  from	  Idiocy	  and	  its	  
treatment	  by	  the	  physiological	  method.	  
•  Walter	  Frank	  Raphael	  Weldon	  1902	  –	  “the	  
accumulaYon	  of	  records,	  in	  which	  results	  are	  
massed	  together	  in	  ill-­‐defined	  categories	  of	  
variable	  and	  uncertain	  extent,	  can	  only	  result	  
in	  harm”.	  
Diagnos*c	  Criteria	  for	  299.00	  Au*s*c	  Disorder	  
	  
Diagnos)c	  and	  Sta)s)cal	  Manual	  of	  Mental	  Disorders:	  DSM	  IV	  
	  (I)	  A	  total	  of	  six	  (or	  more)	  items	  from	  (A),	  (B),	  and	  (C),	  with	  at	  least	  two	  from	  (A),	  and	  one	  each	  from	  (B)	  and	  (C)	  
	  
(A)	  qualitaYve	  impairment	  in	  social	  interacYon,	  as	  manifested	  by	  at	  least	  two	  of	  the	  following:	  
1.	  marked	  impairments	  in	  the	  use	  of	  mulYple	  nonverbal	  behaviors	  such	  as	  eye-­‐to-­‐eye	  gaze,	  facial	  expression,	  body	  posture,	  and	  gestures	  to	  
regulate	  social	  interacYon	  
2.	  failure	  to	  develop	  peer	  relaYonships	  appropriate	  to	  developmental	  level	  
3.	  a	  lack	  of	  spontaneous	  seeking	  to	  share	  enjoyment,	  interests,	  or	  achievements	  with	  other	  people,	  (e.g.,	  by	  a	  lack	  of	  showing,	  bringing,	  or	  
poinYng	  out	  objects	  of	  interest	  to	  other	  people)	  	  
4.	  lack	  of	  social	  or	  emoYonal	  reciprocity	  (	  note:	  in	  the	  descripYon,	  it	  gives	  the	  following	  as	  examples:	  not	  acYvely	  parYcipaYng	  in	  simple	  
social	  play	  or	  games,	  preferring	  solitary	  acYviYes,	  or	  involving	  others	  in	  acYviYes	  only	  as	  tools	  or	  "mechanical"	  aids	  )	  
	  
(B)	  qualitaYve	  impairments	  in	  communicaYon	  as	  manifested	  by	  at	  least	  one	  of	  the	  following:	  	  
1.	  delay	  in,	  or	  total	  lack	  of,	  the	  development	  of	  spoken	  language	  (not	  accompanied	  by	  an	  aUempt	  to	  compensate	  through	  alternaYve	  
modes	  of	  communicaYon	  such	  as	  gesture	  or	  mime)	  
2.	  in	  individuals	  with	  adequate	  speech,	  marked	  impairment	  in	  the	  ability	  to	  iniYate	  or	  sustain	  a	  conversaYon	  with	  others	  
3.	  stereotyped	  and	  repeYYve	  use	  of	  language	  or	  idiosyncraYc	  language	  
4.	  lack	  of	  varied,	  spontaneous	  make-­‐believe	  play	  or	  social	  imitaYve	  play	  appropriate	  to	  developmental	  level	  
	  
(C)	  restricted	  repeYYve	  and	  stereotyped	  paUerns	  of	  behavior,	  interests	  and	  acYviYes,	  as	  manifested	  by	  at	  least	  two	  of	  the	  following:	  	  
1.	  encompassing	  preoccupaYon	  with	  one	  or	  more	  stereotyped	  and	  restricted	  paUerns	  of	  interest	  that	  is	  abnormal	  either	  in	  intensity	  or	  
focus	  
2.	  apparently	  inflexible	  adherence	  to	  specific,	  nonfuncYonal	  rouYnes	  or	  rituals	  
3.	  stereotyped	  and	  repeYYve	  motor	  mannerisms	  (e.g	  hand	  or	  finger	  flapping	  or	  twisYng,	  or	  complex	  whole-­‐body	  movements)	  
4.	  persistent	  preoccupaYon	  with	  parts	  of	  objects	  
	  
(II)	  Delays	  or	  abnormal	  funcYoning	  in	  at	  least	  one	  of	  the	  following	  areas,	  with	  onset	  prior	  to	  age	  3	  years:	  	  
(A)	  social	  interacYon	  
(B)	  language	  as	  used	  in	  social	  communicaYon	  
(C)	  symbolic	  or	  imaginaYve	  play	  
	  
(III)	  The	  disturbance	  is	  not	  beUer	  accounted	  for	  by	  ReU's	  Disorder	  or	  Childhood	  DisintegraYve	  Disorder	  
OBSERVATIONS ON AN ETHNIC CLASSIFICATION OF IDIOTS *
J. LANGDON H. DOWN M.D., London
THOSE who have given any attention to congenital mental lesions, must have
been frequently puzzled how to arrange, in any satisfactory way, the different
classes of this defect which may have come under their observation. Nor
will the difficulty be lessened by an appeal to what has been written on the
subject. The systems of classification are generally so vague and artificial,
that, not only do they assist but feebly, in any mental arrangement of the
phenomena which are presented, but they completely fail in exerting anypractical influence on the subject.
The medical practitioner who may be consulted in any given case, has,
perhaps in a very early condition of the child's life, to give an opinion on
points of vital importance as to the present condition and probable future of
the little one. Moreover, he may be pressed as to the question, whether the
supposed defect dates from any cause subsequent to the birth or not. Has
the nurse dosed the child with opium? Has the little one met with any
accident? Has the instrumental interference which maternal safety de-
manded, been the cause of what seems to the anxious parents, a vacant future?
Can it be that when away from the family attendant the calomel powders
were judiciously prescribed? Can, in fact, the strange anomalies which the
child presents, be attributed to the numerous causes which maternal solici-
tude conjures to the imagination, in order to account for a condition, for
which any cause is sought, rather than hereditary taint or parental influence.
Will the systems of classification, either all together, or any one of them,
assist the medical adviser in the opinion he is to present, or the suggestions
which he is to tender to the anxious parent? I think that they will entirely
fail him in the matter, and that he will have in many cases to make a guarded
diagnosis and prognosis, so guarded, in fact, as to be almost valueless, or to
venture an authoritative assertion which the future may perhaps confirm.
I have for sometime had my attention directed to the possibility of
making a classification of the feeble minded by arranging them around
various ethnic standards—in other words, framing a natural system to
supplement the information to be derived by an inquiry into the history of
the case.
I have been able to find among the large number of idiots and imbeciles
which come under my observation, both at Earlswood and the out-patient
department of the Hospital, that a considerable portion can be fairly re-
ferred to one of the great divisions of the human family other than the class
from which they have sprung. Of course, there are numerous representatives
of the great Caucasian family. Several well-marked examples of the Ethi-
opian variety have come under my notice, presenting the characteristic
malar bones, the prominent eyes, the puffy lips, and retreating chin. The
* This paper from the London Hospital Clinical Report 3, 259-262 (i866) is republishedon account of its historical interest (see page 698). The editors are indebted to Dr J. H.
Edwards, The Medical School, University of Birmingham who proposed republication and
provided the copy.
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The life expectancy, however, is far below the average, and the tendency is
to the tuberculosis, which I believe to be the hereditary origin of the
degeneracy.Apart from the practical bearing of this attempt at an ethnic classification,
considerable philosophical interest attaches to it. The tendency in the
present day is to reject the opinion that the various races are merely varieties
of the human family having a common origin, and to insist that climatic,
or other influences, are insufficient to account for the different types of man.
Here, however, we have examples of retrogression, or at all events, of de-
parture from one type and the assumption of the characteristics of another.
If these great racial divisions are fixed and definite, how comes it that disease
is able to break down the barrier, and to simulate so closely the features os
the members of another division. I cannot but think that the observations
which I have recorded are indications that the differences in the races are not
specific but variable.
These examples of the result of degeneracy among mankind, appear to me
to furnish some arguments in favour of the unity of the human species.
London Hospital Cli ical Lecture Report. 3, 259-262, i866.
2Y
“Those	  who	  hav 	  given	  any	  aU nY n	  to	  congenital	  mental	  
lesions,	  must	  have	  been	  frequently	  puzzled	  how	  to	  arrange,	  in	  
any	  saYsfactory	  way,	  the	  different	  classes	  of	  this	  defect	  which	  
may	   ave	  come	  under	  their	  observaYon.	  Nor	  will	  the	  difficulty	  be	  
lessened	  by	  an	  appeal	  to	  what	  has	  been	  wriUen	  on	  the	  subject.	  
The	  systems	  of	  classificaYon	  are	  generally	  so	  vague	  and	  arYficial,	  
that,	  not	  only	  do	  they	  assist	  but	  feebly,	  in	  any	  mental	  
arra gement	  of	  the	  phenomena	  represented,	  but	  they	  
completely	  fail	  in	  exerYng	  a y	  pracYcal	  influenc 	  on	  the	  subject.”	  
	  
	  
